Medicine’s David Blumenthal discusses new rheumatoid arthritis drug

Pfizer’s arthritis pill backed by U.S. FDA advisory panel

Bloomberg Businessweek: An expert advisory panel recommended U.S. regulators approve Pfizer Inc.’s experimental drug to treat rheumatoid arthritis. Though the pill does raise safety concerns, “This is as good as is possible at this stage in the game,” said David Blumenthal, assistant professor of medicine.